A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Cetuximab is typically administered on a weekly schedule for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab administered every 2 weeks (q2w). In this multicenter randomized prospective phase II study, eligible patients (≤2 prior cytoto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Compr Canc Netw
Main Authors: Fury, Matthew G., Sherman, Eric, Lisa, Donna, Agarwal, Neeraj, Algazy, Kenneth, Brockstein, Bruce, Langer, Corey, Lim, Dean, Mehra, Ranee, Rajan, Sandeep K., Korte, Susan, Lipson, Brynna, Yunus, Furhan, Tanvetyanon, Tawee, Smith-Marrone, Stephanie, Ng, Kenneth, Xiao, Han, Haque, Sofia, Pfister, David G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5726232/
https://ncbi.nlm.nih.gov/pubmed/23138167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados